HBA and Healthcare Companies Partner in Gender Parity Collaborative
The Healthcare Businesswomen’s Association (HBA) announced that 12 healthcare and life science companies have started a partnership to advance gender parity progress in the industry. The founding member companies serve as role models with all 12 organizations supporting internal women’s leadership networks and more than half recognized by national business media outlets for progressive diversity and inclusion programs, along with representing a work force of more than 750,000 employees collectively globally.
While similar corporate partnerships exist, the HBA’s Collaborative is different in that all member companies are in the healthcare and life science business. The twelve founding member companies are Advanced Clinical, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, GlaxoSmithKline, Medidata Solutions, Novartis, Pfizer, Quest Diagnostics, Genentech, a member of the Roche group, and Sanofi.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
